PRINCETON, N.J., December 20, 2021 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointments of Heather Graham as Vice President, Regulatory Writing and Scientific Publication and Laura Sheppard as Senior Director, Global Submission to advance its growth strategy. Certara helps to assure and accelerate the approval of medical innovations through regulatory writing and submission solutions, powered by technology.
“The regulatory science team is thrilled to have Heather and Laura join our dynamic group of regulatory scientists and medical experts,” said Demetrius Carter, Senior Vice President of Regulatory Services at Certara. “I am confident that they will assist in deepening our regulatory science expertise and further our commitment to quality and operational excellence for our clients. We look forward to the insights Heather and Laura will bring to solving the challenges facing our clients in the evolving global regulatory environment.”
Heather Graham brings more than 16 years of regulatory science and medical writing experience to her position at Certara. She previously served as the Global Head of Regulatory Documentation at Roche, where she led the company’s global medical writing team and supported the delivery of regulatory documents and content across their broad portfolio of products. In her new role at Certara Synchrogenix, Heather will lead the expansion of our global regulatory writing and scientific publications teams. Heather will also provide oversight and governance to many of our key strategic partnerships. In addition, Heather will play a pivotal role in attracting talent within the Certara Synchrogenix division. Ms. Graham received her bachelor’s degree in biology and master’s degree in molecular biology from York University in Toronto.
Laura Sheppard is an experienced medical writer with more than 15 years of regulatory writing and project management expertise. At Certara Synchrogenix, Laura will be a member of the Company’s growing Global Submissions team responsible for leading more than 50 regulatory and marketing applications annually. She joins Certara from Endo Pharmaceuticals, where she was the Senior Director of Medical Writing, Document Quality Control, and Clinical Transparency for almost four years. Before that, she was the Director of Medical Writing and Quality Control at Mallinckrodt Pharmaceuticals. Laura is active in the American Medical Writing Association (AMWA) and is currently serving her third term as a Director-at-Large with the Board of Directors assisting with the implementation of annual plans, policies and functions of AMWA. Ms. Sheppard received her MBA from Saint Louis University and master’s degree in secondary education from Lindenwood University in St. Charles, Missouri.
Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
Jieun W. Choe